Raven Jaeger - 07 Jun 2022 Form 4 Insider Report for Diffusion Pharmaceuticals Inc. (CRVO)

Role
Chief Regulatory Officer
Signature
/s/ William R. Elder, attorney-in-fact for the Reporting Person
Issuer symbol
CRVO
Transactions as of
07 Jun 2022
Net transactions value
$0
Form type
4
Filing time
26 Aug 2022, 18:08:07 UTC
Previous filing
26 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DFFN Stock Option (Right to Buy) Award $0 +8,000 $0.000000 8,000 07 Jun 2022 Common Stock 8,000 $7.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the options will vest in 36 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a 36-month period beginning June 30, 2022.